Abstract
One of the main limitations of the highly used cancer imaging technique, PET-CT, is its inability to distinguish between cancerous lesions and post treatment inflammatory conditions. The reason for this lack of specificity is that [18F]FDG-PET is based on increased glucose metabolic activity, which characterizes both cancerous tissues and inflammatory cells. To overcome this limitation, we developed a nanoparticle-based approach, utilizing glucose-functionalized gold nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our approach demonstrates specific tumor targeting and has successfully distinguished between cancer and inflammatory processes in a combined tumor-inflammation mouse model, due to dissimilarities in angiogenesis occurring under different pathologic conditions. This study provides a set of capabilities in cancer detection, staging and follow-up, and can be applicable to a wide range of cancers that exhibit high metabolic activity.
Original language | English |
---|---|
Pages (from-to) | 3469-3477 |
Number of pages | 9 |
Journal | ACS Nano |
Volume | 10 |
Issue number | 3 |
DOIs | |
State | Published - 22 Mar 2016 |
Bibliographical note
Publisher Copyright:© 2016 American Chemical Society.
Funding
This work was partially supported by the Research and Development Chief Scientist Kamin grant (49544), by the Israel Cancer Research Fund (ICRF), by the Israel Science Foundation grant (749/14), and by the doctoral scholarship for applicable and scientific engineering research, granted to Tamar Dreifuss and Oshra Betzer by the Ministry of Science, Technology & Space, Israel.
Funders | Funder number |
---|---|
Research and Development Chief Scientist Kamin | 49544 |
Israel Cancer Research Fund | |
Ministry of Science, Technology and Space | |
Israel Science Foundation | 749/14 |
Keywords
- CT
- FDG-PET
- cancer
- gold nanoparticles
- metabolic-based imaging